News

Sarepta Sinks as Third Patient Death Stirs Transparency Concerns
A third patient has died this year after getting a gene therapy from Sarepta Therapeutics Inc., raising questions about the ...
Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More
Stocks traded mixed Friday as investors focused on corporate earnings, a day after the S&P 500 and Nasdaq Composite set ...
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...
Fierce Biotech5h
Chutes & Ladders—Sarepta shakes up C-suite amid organization overhaul
Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...
Explore more
Sarepta Therapeutics to Restructure, Lay Off 500 Workers
The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.
Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...